Several Milestones on Horizon for 'Top Pick' Immunotherapy Firm

Research Report
  ()
Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status. read more >

Test for Personalized Approach to Hodgkin's Lymphoma Treatment Entering Final Stages Before Commercialization

  ()
One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment. read more >

Firm Focused on Women's Health Posts 'Record' Sales of Treatment Device

  ()
A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts. read more >

2018 Biotech Watchlist: 'No One Space Is Going to Dominate'

  ()
Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors. read more >

Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018

Contributed Opinion
  ()
As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. read more >

Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's'

Research Report
  ()
André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug. read more >

Portfolio Manager's Biotech Watchlist Picks for 2018

  ()
StoneCastle Investment Management has a high-growth fund that invests wherever it finds opportunities, and it is bullish on healthcare. In this interview with The Life Sciences Report, portfolio manager Bruce Campbell highlights four companies that he is putting on Streetwise Reports' 2018 Biotech Watchlist. read more >
Expert Investing Ideas

"RXII's sd-rxRNA can augment already amazing results in immunotherapy."

–John Vandermosten, Zacks Small-Cap Research


"We are initiating coverage on RVX with a Buy rating."

–David Kideckel, Beacon Securities Ltd.


Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

2017: A Year of Triple Digit Stock Performance

  ()
As stock indexes in the U.S. hit record highs in 2017, we take a look at some of the best performers profiled by Streetwise Reports in the last year, some of which have seen triple digit increases. read more >

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA

Research Report
  ()
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect. read more >

Biotech's Shares 'Undervalued' and Positioned for 'Long-Term Upside Potential'

Research Report
  ()
Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease. read more >

'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform

Research Report
  ()
Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. read more >